Will Amkor repurchase more than $150M of its $300M buyback authorization in 2026?

AMKR has been a conservative cash steward for years; this is the first material buyback in several cycles. Authorization on 4/23/2026 leaves ~8 months to deploy $150M ($18.75M/month). The stock has rallied +60% to $71.33 since March, which makes opportunistic buying expensive. AMKR's historical pattern suggests opportunistic-only rather than programmatic 10b5-1 — and opportunistic buyers typically slow at high prices. H2 is peak capex draw with ~$1.75-$2.1B going into facilities. Authorizations regularly run multi-year. I lean below coin-flip — 42%.

The size of the authorization ($300M) signals deployment intent — a smaller authorization would have been chosen if execution wasn't planned. The Board approving this in the peak capex year is a meaningful signal: management views FCF visibility as strong enough to fund both. The $1.8B starting cash position and 1.1x leverage provide ample capacity even with H2 capex draw. Working against this: announcing a buyback at all-time highs (post 60% rally) is somewhat of a defensive posture vs paying down debt or dividend. The execution path matters — if a 10b5-1 plan is adopted, $150M is easily deployable; if opportunistic, less so. Coin-flip.

Tail-risk consideration: the buyback timing — announced just before the Q1 print — suggests the Board had visibility into the strong Q1 result before authorizing. This raises the bar for what 'success' execution looks like. However, AMKR is now entering its biggest capex year ($2.5-3B) in company history, with materials supply pressure flagged for H2 and Middle East geopolitical concerns. A prudent CFO would conserve cash. Also, the 60% YTD rally makes buying expensive — historical executions tend to slow when stock is up. The 10b5-1 vs opportunistic question is binary: if they adopt 10b5-1, $150M is easy; if opportunistic, the rally is a deterrent. I weight ~40% reflecting AMKR's conservative DNA.

Industry base rate for $300M-class semi authorizations: typically 40-60% executed in the first 12 months when stock is at fair value or below. With AMKR up 60% YTD, the rate likely skews lower toward the bottom of that range. $150M / 8 months = $18.75M/month — achievable but requires consistent buying. Historical AMKR conservatism + peak capex year + rally combine to suggest sub-50% execution is more likely than not. ~45% probability of exceeding $150M.

The authorization itself is the major signal; execution pace is the open question. $1.8B cash and 1.1x leverage easily afford $150M without strain. Management explicitly framed liquidity as ample alongside the authorization. However, only 8 months remain in calendar 2026 (vs 12 months for typical first-year base rates), making the calendar-year threshold tighter than first-year. The buyback was timed to coincide with the strong Q1 — possibly meant as a sentiment signal more than a programmatic deployment plan. Slightly below coin-flip.

Triangulating on capital deployment signals: Q1 D/EBITDA fell to 1.1x and operating cash flow is strong, supporting capacity. But the 60% rally and peak capex draw argue for restraint. Investor Day on May 21 may add a multi-year capital allocation framework that recalibrates expectations either direction. AMKR's historical conservatism is the dominant prior — any deviation needs to be earned through evidence. Net ~46% probability of exceeding $150M.

$150M = 50% of authorization in 8 months. Possible but AMKR is conservative and stock rallied 60%. Below coin-flip.

Balance sheet supports $150M easily. Authorization is the signal. But peak capex year and rally are real offsets. Coin-flip.

Authorizations often run multi-year. $300M sized to cover full cycle, not all 2026. AMKR conservative. ~42%.